Skip to main content

Table 6 Summary of maximum adverse events during dendritic cell treatment and follow-up

From: Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma

Adverse event

Grade 1

Grade 2

Fatigue

1 (1)

1 (1)

Nausea

1 (2)

1 (1)

Anorexia

 

1 (1)

Arthralgia

1 (1)

 

Confusion

1 (1)

 

Diarrhea, colostomy

1 (1)

 

Diarrhea, no colostomy

1 (2)

 

Hemorrhage

1 (2)

 

Injection site Rxn

1 (1)

 

Myalgia

 

1 (1)

Pain-abdominal

 

1 (2)

Pain-bone

1 (1)

 

Speech

 

1 (1)

Vomiting

1 (1)

 

Wound, infectious

1 (1)

 
  1. Numbers in parentheses indicate the cycle of vaccination when the adverse event occurred. No grade 3 or Grade 4 adverse reactions were observed.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us